RheumNow

Rheumnow.com serves as a dedicated news platform focused on Rheumatology. Crafted by specialists in the field, it caters to Rheumatologists and professionals in related areas. The site offers daily updates, and you can also receive the latest news directly in your inbox by subscribing to our newsletter.

Trade/B2B

English

Online/Digital

Outlet metrics

Domain Authority

Ranking

Global

#1344235

United States

#462120

Health/Health

#7911

Traffic sources

Monthly visitors

Articles

What would it take for JAKs to ROCK the boat?

1 week ago | rheumnow.com | David Liew

JAK inhibitors have taken a beating over the last three years. The excitement and potential has been tempered by mounting cardiovascular safety concerns, but specifically in at-risk patients, compared to TNF inhibitors. Once the suggestion is made, though, the concern is powerful. I am sure I am not the only one who has had to have difficult conversations navigating nuance in explaining situations where I think the risk is more than manageable. The fear of cardiovascular events can be hard to shake.
Nurse-Led Treat-to-Target Clinics | RheumNow

1 week ago | rheumnow.com | Jack Cush

New studies shared at the 2025 annual EULAR congress in Barcelona reinforce that position, highlighting the benefits that nurse-led care can bring for both patients and healthcare systems. Nurse-led care and self-monitoring can both support treat-to-target (T2T) approaches.2,3 Combining self-monitoring with nurse support during the initiation of urate-lowering therapy in people with gout could help reduce physician visits and costs while maintaining or improving quality of care.
EULAR 2025 – Day 4 Report | RheumNow

1 week ago | rheumnow.com | Jack Cush

Saturday was the final day of EULAR, and included several lectures, but mostly late breaking abstracts and new EULAR guidelines - notably on Rheumatoid Arthritis and another on Interstitial Lung disease in connective tissue disorders. My favorite presentations included the following:EULAR Recommendations for the Management of Familial Mediterranean Fever (FMF)The take-home high points were:FMF should be diagnosed and initially treated by an FMF experienced physician.
Pregnancy outcomes in autoinflammatory disease

1 week ago | rheumnow.com | Jack Cush

To address this, a French multi-centre prospective pregnancy observational cohort was set up, to analyse disease activity, treatment, pregnancy outcomes, delivery, and neonatal health. The work – presented at the 2025 annual congress of EULAR – showcased findings from 97 women with an autoinflammatory disease.
EULAR 2025 – Day 3 Report | RheumNow

2 weeks ago | rheumnow.com | Jack Cush

Highlights from today included presentations on imaging in vasculitis, a debate on whether to treat high risk pre-clinical RA, and EULAR Recommendations on a) Treatment of interstitial lung disease (ILD); b) Physical Activity in people with arthritis; and c) EULAR disease activity score for antiphospholipid syndrome and d) the management of SLE nephritis (look for these on RheumNow.com or follow us on twitter). Below are a few others that caught my eye today.
Expanding the IL-17 Therapeutic Landscape

2 weeks ago | rheumnow.com | Adela Castro

IL-17 inhibitors are an effective therapeutic for a broad spectrum of inflammatory and autoimmune diseases and its blockade has revolutionized management of diseases such as psoriasis, psoriatic arthritis and SpA. Currently, four IL-17 inhibitors are approved, particularly for the management of moderate-to-severe plaque psoriasis and spondyloarthropathies. Secukinumab and Ixekizumab are both monoclonal antibodies directly targeting IL-17A.
Social Determinants of Health in SLE

2 weeks ago | rheumnow.com | Jack Cush

Social determinants of health (SDH), such as socioeconomic status and educational background are factors that are increasingly recognised as critical contributors to health outcomes in chronic diseases. Understanding how certain factors impact different RMDs is important, and new research into this for both systemic lupus erythematosus (SLE) and inflammatory arthritis was presented at the 2025 annual EULAR congress in Barcelona.
EULAR 2025 – Day 2 Report | RheumNow

2 weeks ago | rheumnow.com | Jack Cush

Day 2 was a full agenda for those attending EULAR 2025 in Barcelona with sessions on the management of RA, Behcets, Lupus and Hand Osteoarthritis. Clinical overviews on MAS, Ehlers-Danlos, Difficult to treat RA and PsA offered a wide variety of options to rheumatologists. Here are a few interesting presentations from today:Neuroimmune Modulation in RESET-RA StudyOP0190 was a phase 3 trial that assessed Vegas nerve stimulation as a means of improving active rheumatoid arthritis (RA).
Secukinumab promise in PMR is real

2 weeks ago | rheumnow.com | David Liew

GCA is getting steroid-sparing therapy choices, and PMR doesn’t want to miss out. Most PMR patients with current therapy approaches incur multiple grams of cumulative prednisolone exposure, even though they’re often exactly the kind of patients we would rather keep away from steroids altogether. Yet we only recently got our first steroid-sparing choice in PMR, sarilumab, and conventional registration studies seem hard to run.
Intraarticular IL-1Ra Gene Therapy in Knee Osteoarthritis

2 weeks ago | rheumnow.com | Jack Cush

De la Vega et al. have published in Science Translational Medicine the efficacy of an IL-1Ra gene therapy in adults with knee osteoarthritis (OA). In a dose-escalation trial in nine participants, they observed that a single intra-articular injection of the gene product led to an increase in IL-1Ra in the synovial fluid that remained elevated for up to a year. There were no serious adverse events related to the gene delivery.